Paper26324372
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
Kelly K and 15 others. J Clin Oncol, 2015. Cited by 381 papers, by iCite.
Cite this record
ConductScience Library. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. Papers, record 26324372. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26324372
- Disease
- non-small cell lung carcinoma1,066 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
- PubMed
- Publication types
- Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Erlotinib Hydrochloride | Major topic |
| Lung Neoplasms | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Chemotherapy, Adjuvant | |
| Double-Blind Method | |
| ErbB Receptors | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| International Agencies | |
| Male | |
| Middle Aged | |
| Mutation | |
| Neoplasm Staging | |
| Prognosis | |
| Survival Rate | |
| Young Adult |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00373425 | A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections3
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 26438112 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non-Small-Cell Lung Cancer. | https://conductscience.org/library/papers/26438112 | PubMed |
| Comment in | 26552954 | Adjuvant TKIs in NSCLC: what can we learn from RADIANT? | https://conductscience.org/library/papers/26552954 | PubMed |
| Comment in | 27568486 | Have adjuvant tyrosine kinase inhibitors lost their shine? | https://conductscience.org/library/papers/27568486 | PubMed |
Cited by220
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 381 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42894004 | Oncogenic mutations in non-small cell lung cancer: from molecular mechanisms to clinical practice. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42894004 | PubMed |
| 42867814 | A Podcast on Osimertinib After CRT in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): Current and Future Perspectives. | Target Oncol | 2026 | https://conductscience.org/library/papers/42867814 | PubMed |
| 42700335 | The Efficacy of Adjuvant EGFR-TKI Therapy for Stage IA Lung Adenocarcinoma with EGFR Mutations: A Retrospective Cohort Study. | Ann Surg Oncol | 2026 | https://conductscience.org/library/papers/42700335 | PubMed |
| 42660909 | Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42660909 | PubMed |
| 42625890 | Efficacy and safety of almonertinib as adjuvant therapy in stage II-IIIA EGFR-mutant non-small cell lung cancer: a retrospective study. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42625890 | PubMed |
| 42588620 | Targeting Classical EGFR Mutations in Lung Cancer: Twenty Years of Progress and Beyond. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588620 | PubMed |
| 42564402 | Target-specific cardiotoxicity of tyrosine kinase inhibitors: a Systematic Review and meta-analysis. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42564402 | PubMed |
| 42299229 | Adjuvant epidermal growth factor receptor tyrosine kinase inhibitor in resected stage N2 non-small cell lung cancer harboring EGFR mutation. | Transl Lung Cancer Res | 2026 | https://conductscience.org/library/papers/42299229 | PubMed |
| 42038290 | Clinical efficacy of comprehensive traditional Chinese medicine in adjuvant therapy for stage Ib-IIIa resected non-small cell lung cancer: a multi-center, randomized, double-blind, placebo-controlled trial. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42038290 | PubMed |
| 41964727 | Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC). | Curr Oncol Rep | 2026 | https://conductscience.org/library/papers/41964727 | PubMed |
| 41953249 | Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With EGFR Mutation (West Japan Oncology Group 11719L: ADJUST Study). | JTO Clin Res Rep | 2026 | https://conductscience.org/library/papers/41953249 | PubMed |
| 41736521 | Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026). | Chin Med J (Engl) | 2026 | https://conductscience.org/library/papers/41736521 | PubMed |
| 41701181 | CyberKnife radical cure for early lung adenocarcinoma: a case was confirmed by postoperative pathology. | Lung Cancer Manag | 2026 | https://conductscience.org/library/papers/41701181 | PubMed |
| 41681965 | Neoadjuvant, Adjuvant and Perioperative Treatment in Early-Stage Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations: Current Landscape and Future Perspectives. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41681965 | PubMed |
| 41590340 | A Canadian Perspective on Perioperative Systemic Therapy in Resectable Non-Small Cell Lung Cancer. | Curr Oncol | 2025 | https://conductscience.org/library/papers/41590340 | PubMed |
| 40866342 | Adjuvant icotinib for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/40866342 | PubMed |
| 40596078 | A network meta-analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non-small cell lung cancer. | Sci Rep | 2025 | https://conductscience.org/library/papers/40596078 | PubMed |
| 40565872 | Systemic Therapy for Operable NSCLC: A Review of the Literature and Discussion of Future Directions. | J Clin Med | 2025 | https://conductscience.org/library/papers/40565872 | PubMed |
| 40524802 | Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoma with micropapillary or solid histological subtypes: a single-center, single-arm, phase 2 trial. | EClinicalMedicine | 2025 | https://conductscience.org/library/papers/40524802 | PubMed |
| 40507325 | Perioperative Strategies in Resectable Non-Squamous Non-Small Cell Lung Cancer with EGFR Mutations and ALK Rearrangement. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40507325 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| ERLOTINIB | CHEMBL553 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL553 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26324372
GET https://conductscience.org/api/papers/v1/26324372/cited_by?page=2